Background Image
Banner Image
TAP TO UNMUTE volume_off volume_up

Program Note: This is for informational purposes only, and NYSE does not recommend any investments or investment strategies.

Join theCUBE + NYSE Wired at the New York Stock Exchange as biotechnology, pharmaceutical and life sciences leaders examine how artificial intelligence is reshaping drug discovery and development. This series explores how companies are using advanced computing, data and automation to identify promising therapies, improve clinical research and bring new treatments to patients more efficiently.

Our coverage focuses on what it takes to move innovation from the laboratory into the market, including scientific validation, regulatory approval, funding and commercialization. The emphasis is on practical progress over technological promise: where AI is delivering measurable results, which business models are gaining traction, and how the convergence of biology and technology is changing the economics of medicine.

Speakers
HOST
Gemma Allen

Gemma Allen

Host, theCUBE + NYSE Wired

theCUBE

Ron Alfa

Ron Alfa

Co-Founder & CEO

NOETIK AI

Kärt Tomberg

Kärt Tomberg

CEO & Co-Founder

ExpressionEdits

Gleb Kuznetsov

Gleb Kuznetsov

Co-Founder & CEO

Manifold Bio

Linda Goodman

Linda Goodman

Co-Founder & CTO

Fauna Bio

Cheri Ackerman Araromi

Cheri Ackerman Araromi

CEO & Co-Founder,

Concerto Biosciences

Jim Iversen

Jim Iversen

CEO

Sen-Jam Pharmaceutical

Mary Rozenman

Mary Rozenman

CFO/CBO

insitro

Jacob Oppenheim

Jacob Oppenheim

Venture Partner

RA Ventures

Errik Anderson

Errik Anderson

Founder, CEO and Chairman,

Alloy Therapeutics